Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Aptevo Therapeutics Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 13 | 8 | −5 |
| Shares | 48.5K | 19.6K | −28.9K (−59.5%) |
| Value | $208.7K | $22.8K | −$185.9K (−89.1%) |
New holders (2)
Institutions that held Aptevo Therapeutics Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 10,526 | $12.2K | 0.00% |
| Clear Street LLC | 2,800 | $3.25K | 0.00% |
Sold out (7)
Institutions that held Aptevo Therapeutics Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Virtu Financial LLC | 21,627 | $93.0K |
| HRT Financial LP | 12,324 | $53.0K |
| JPMorgan Chase & Co | 4,529 | $19.5K |
| Diadema Partners LP | 4,050 | $17.5K |
| UBS Group AG | 783 | $3.38K |
| Center for Financial Planning, Inc. | 5 | $22 |
| Danske Bank A/S | 1 | $4 |